secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sigilon Therapeutics, Inc. (—)
CIK:        0001821323
Form:       8-K
Filed at:   2023-05-22T23:59:59+00:00
Accession:  0001558370-23-010309
Event type: debt
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.02, 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sigilon repays $16.4M Oxford loan early; files 1-for-13 reverse stock split
---------------------------------------------------------------------------

- Repaid $16.4M to Oxford Finance for $20M term loan; all obligations terminated.
- Cash and marketable securities of $56.4M as of March 31 expected to fund operations into 2025.
- Stockholders approved 1-for-13 reverse stock split effective May 23, 2023.
- Directors Douglas Cole and Stephen Oesterle elected; PricewaterhouseCoopers ratified as auditor.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1821323/000155837023010309/0001558370-23-010309-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1821323/000155837023010309/sgtx-20230519x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-010309

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer